荷兰东南部心脏登记(ZON-HR)的设计和基本原理。

IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Netherlands Heart Journal Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI:10.1007/s12471-025-01934-7
Eva C I Woelders, Denise A M Peeters, Sanne Janssen, Jasper J P Luijkx, Patty J C Winkler, Peter Damman, Wouter S Remkes, Arnoud W J van 't Hof, Robert Jan M van Geuns
{"title":"荷兰东南部心脏登记(ZON-HR)的设计和基本原理。","authors":"Eva C I Woelders, Denise A M Peeters, Sanne Janssen, Jasper J P Luijkx, Patty J C Winkler, Peter Damman, Wouter S Remkes, Arnoud W J van 't Hof, Robert Jan M van Geuns","doi":"10.1007/s12471-025-01934-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In patients undergoing percutaneous coronary intervention (PCI), personalised medicine is key to the secondary prevention of ischaemic and bleeding events. To provide an extensive overview of the quality of secondary prevention and of personalised medicine, a consortium in the southeastern region of the Netherlands has created a PCI registry: the South-East Netherlands Heart Registry (Zuid-Oost Nederland Hart Registratie, ZON-HR).</p><p><strong>Aim: </strong>To visualise and improve personalised secondary prevention post-PCI, focussing on key elements such as antiplatelet treatment, cholesterol management and comorbidities such as diabetes mellitus.</p><p><strong>Design and population: </strong>A prospective multicentre registry of all consecutive patients undergoing PCI at 4 participating PCI centres and 3 referral centres.</p><p><strong>Treatment: </strong>Interventional procedures and concomitant pharmaceutical treatment are performed in accordance with the guidelines. The ZON-HR promotes risk stratification after PCI using a simplified protocol for a personalised antiplatelet strategy.</p><p><strong>Data collection and quality: </strong>Demographics, laboratory values, baseline procedural characteristics and pharmaceutical treatment data are collected. Outcomes include thromboembolic and bleeding complications and medication changes. Data are pseudonymised, and a clinical event committee will review 20% of the adverse events (randomly selected).</p><p><strong>Strengths and weaknesses: </strong>This registry represents the entire PCI population and visualises gaps in secondary prevention. Weaknesses are the collection of outcomes and medication changes using mostly patient-reported outcomes.</p><p><strong>Conclusion: </strong>The ZON-HR is a comprehensive PCI registry that provides baseline and follow-up data of a large PCI cohort in the southeastern region of the Netherlands. The ZON-HR aims to improve secondary prevention after PCI and augment personalised treatment that focusses on key elements of secondary prevention.</p>","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"76-84"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845330/pdf/","citationCount":"0","resultStr":"{\"title\":\"Design and rationale of the South-East Netherlands Heart Registry (ZON-HR).\",\"authors\":\"Eva C I Woelders, Denise A M Peeters, Sanne Janssen, Jasper J P Luijkx, Patty J C Winkler, Peter Damman, Wouter S Remkes, Arnoud W J van 't Hof, Robert Jan M van Geuns\",\"doi\":\"10.1007/s12471-025-01934-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In patients undergoing percutaneous coronary intervention (PCI), personalised medicine is key to the secondary prevention of ischaemic and bleeding events. To provide an extensive overview of the quality of secondary prevention and of personalised medicine, a consortium in the southeastern region of the Netherlands has created a PCI registry: the South-East Netherlands Heart Registry (Zuid-Oost Nederland Hart Registratie, ZON-HR).</p><p><strong>Aim: </strong>To visualise and improve personalised secondary prevention post-PCI, focussing on key elements such as antiplatelet treatment, cholesterol management and comorbidities such as diabetes mellitus.</p><p><strong>Design and population: </strong>A prospective multicentre registry of all consecutive patients undergoing PCI at 4 participating PCI centres and 3 referral centres.</p><p><strong>Treatment: </strong>Interventional procedures and concomitant pharmaceutical treatment are performed in accordance with the guidelines. The ZON-HR promotes risk stratification after PCI using a simplified protocol for a personalised antiplatelet strategy.</p><p><strong>Data collection and quality: </strong>Demographics, laboratory values, baseline procedural characteristics and pharmaceutical treatment data are collected. Outcomes include thromboembolic and bleeding complications and medication changes. Data are pseudonymised, and a clinical event committee will review 20% of the adverse events (randomly selected).</p><p><strong>Strengths and weaknesses: </strong>This registry represents the entire PCI population and visualises gaps in secondary prevention. Weaknesses are the collection of outcomes and medication changes using mostly patient-reported outcomes.</p><p><strong>Conclusion: </strong>The ZON-HR is a comprehensive PCI registry that provides baseline and follow-up data of a large PCI cohort in the southeastern region of the Netherlands. The ZON-HR aims to improve secondary prevention after PCI and augment personalised treatment that focusses on key elements of secondary prevention.</p>\",\"PeriodicalId\":18952,\"journal\":{\"name\":\"Netherlands Heart Journal\",\"volume\":\" \",\"pages\":\"76-84\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845330/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Netherlands Heart Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12471-025-01934-7\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Netherlands Heart Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12471-025-01934-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

导读:在接受经皮冠状动脉介入治疗(PCI)的患者中,个体化用药是二级预防缺血和出血事件的关键。为了提供二级预防和个性化医疗质量的广泛概述,荷兰东南部地区的一个联盟创建了一个PCI登记处:荷兰东南部心脏登记处(Zuid-Oost Nederland Hart Registratie, ZON-HR)。目的:可视化和改善pci后的个性化二级预防,重点关注抗血小板治疗、胆固醇管理和糖尿病等合并症等关键因素。设计和人群:一项前瞻性多中心登记,包括所有在4个参与PCI中心和3个转诊中心连续接受PCI治疗的患者。治疗:根据指南进行介入手术和伴随的药物治疗。ZON-HR使用简化的方案促进PCI后的风险分层,以实现个性化抗血小板策略。数据收集和质量:收集人口统计、实验室值、基线程序特征和药物治疗数据。结果包括血栓栓塞和出血并发症以及药物改变。数据是匿名的,临床事件委员会将审查20%的不良事件(随机选择)。优势和劣势:该注册表代表了整个PCI人群,并可视化了二级预防的差距。缺点是主要使用患者报告的结果收集结果和药物变化。结论:ZON-HR是一个全面的PCI注册表,提供了荷兰东南部地区一个大型PCI队列的基线和随访数据。ZON-HR旨在改善PCI后的二级预防,并加强个性化治疗,重点关注二级预防的关键要素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Design and rationale of the South-East Netherlands Heart Registry (ZON-HR).

Introduction: In patients undergoing percutaneous coronary intervention (PCI), personalised medicine is key to the secondary prevention of ischaemic and bleeding events. To provide an extensive overview of the quality of secondary prevention and of personalised medicine, a consortium in the southeastern region of the Netherlands has created a PCI registry: the South-East Netherlands Heart Registry (Zuid-Oost Nederland Hart Registratie, ZON-HR).

Aim: To visualise and improve personalised secondary prevention post-PCI, focussing on key elements such as antiplatelet treatment, cholesterol management and comorbidities such as diabetes mellitus.

Design and population: A prospective multicentre registry of all consecutive patients undergoing PCI at 4 participating PCI centres and 3 referral centres.

Treatment: Interventional procedures and concomitant pharmaceutical treatment are performed in accordance with the guidelines. The ZON-HR promotes risk stratification after PCI using a simplified protocol for a personalised antiplatelet strategy.

Data collection and quality: Demographics, laboratory values, baseline procedural characteristics and pharmaceutical treatment data are collected. Outcomes include thromboembolic and bleeding complications and medication changes. Data are pseudonymised, and a clinical event committee will review 20% of the adverse events (randomly selected).

Strengths and weaknesses: This registry represents the entire PCI population and visualises gaps in secondary prevention. Weaknesses are the collection of outcomes and medication changes using mostly patient-reported outcomes.

Conclusion: The ZON-HR is a comprehensive PCI registry that provides baseline and follow-up data of a large PCI cohort in the southeastern region of the Netherlands. The ZON-HR aims to improve secondary prevention after PCI and augment personalised treatment that focusses on key elements of secondary prevention.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Netherlands Heart Journal
Netherlands Heart Journal CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.70
自引率
5.00%
发文量
84
审稿时长
6-12 weeks
期刊介绍: The scope of the Netherlands Heart Journal is to contribute to the national and international literature by publishing scientific papers in the field of cardiovascular medicine. It also provides a platform for Continuing Medical Education for cardiologists and those in training for the speciality of cardiology in the Netherlands. The Netherlands Heart Journal is made available to cardiologists, cardiologists in training, cardiopulmonary surgeons, cardiopulmonary surgeons in training, internists and paediatric cardiologists. The journal is the official journal of the Netherlands Society of Cardiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信